{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:26:32Z","timestamp":1788405992907,"version":"build-2803163510"},"reference-count":126,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>For many years, the failure of randomized controlled trials (RCTs) has prevented patients with systemic lupus erythematosus (SLE) from benefiting from biological drugs that have proved to be effective in other rheumatological diseases. Only two biologics are approved for SLE, however they can only be administered to a restricted proportion of patients. Recently, several phase II RCTs have evaluated the efficacy and safety of new biologics in extra-renal SLE and lupus nephritis. Six drug trials have reported encouraging results, with an improvement in multiple clinical and serological outcome measures. The possibility of combining B-cell depletion and anti-BLyS treatment has also been successfully explored.<\/jats:p>","DOI":"10.3390\/jcm12093198","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T12:10:03Z","timestamp":1682943003000},"page":"3198","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeted Therapy for SLE\u2014What Works, What Doesn\u2019t, What\u2019s Next"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0681-1472","authenticated-orcid":false,"given":"Veronica","family":"Venturelli","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medical Sciences, Universit\u00e0 degli Studi di Ferrara, Azienda Ospedaliero-Universitaria S. Anna, 44124 Cona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Alan","family":"Isenberg","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology, Department of Medicine, University College London, London WC1E 6JF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: Results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort","volume":"74","author":"Bruce","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/rheumatology\/keab362","article-title":"All-cause and cause-specific mortality in systemic lupus erythematosus: A population-based study","volume":"61","author":"Moghaddam","year":"2021","journal-title":"Rheumatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0021-9681(55)90018-7","article-title":"Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus","volume":"1","author":"Merrell","year":"1955","journal-title":"J. Chronic Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.21955","article-title":"Mortality in systemic lupus erythematosus","volume":"54","author":"Bernatsky","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.autrev.2004.04.002","article-title":"Surviving the butterfly and the wolf: Mortality trends in systemic lupus erythematosus","volume":"3","author":"Borchers","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"ref_6","first-page":"1955","article-title":"Accrual of Organ Damage Over Time in Patients with Systemic Lupus Erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/0961203319860198","article-title":"The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: Factors related to damage accrual in two regional cohorts","volume":"28","author":"Frodlund","year":"2019","journal-title":"Lupus"},{"key":"ref_8","first-page":"524","article-title":"Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort","volume":"59","author":"Segura","year":"2019","journal-title":"Rheumatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","article-title":"Managing rheumatic and musculoskeletal diseases \u2014 past, present and future","volume":"13","author":"Burmester","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.semarthrit.2018.02.014","article-title":"Low disease activity\u2014irrespective of serologic status at baseline\u2014associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study","volume":"48","author":"Fanouriakis","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_12","first-page":"3029","article-title":"Comparative analysis of various brain imaging techniques","volume":"2010","author":"Agnihotri","year":"2010","journal-title":"Annu. Int. Conf. IEEE Eng. Med. Biol. Soc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/acr.22921","article-title":"Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years","volume":"69","author":"Aguiar","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Yusof","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s40744-020-00243-2","article-title":"Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies","volume":"7","author":"Collins","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.55563\/clinexprheumatol\/oassv6","article-title":"Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?","volume":"38","author":"Freitas","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Hennessey, A., Lukawska, J., Cambridge, G., Isenberg, D., and Leandro, M. (2019). Adverse infusion reactions to rituximab in systemic lupus erythematosus: A retrospective analysis. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0082-7"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review","volume":"69","author":"Zeron","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nri3607","article-title":"Apoptotic cell clearance: Basic biology and therapeutic potential","volume":"14","author":"Poon","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrneph.2016.71","article-title":"The role of neutrophils and NETosis in autoimmune and renal diseases","volume":"12","author":"Gupta","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yap, D.Y.H., and Chan, T.M. (2019). B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis\u2014Role in Pathogenesis and Effect of Immunosuppressive Treatments. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246231"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Robinson, R. (2006). Distinct B Cell Receptor Functions Are Determined by Phosphorylation. PLoS Biol., 4.","DOI":"10.1371\/journal.pbio.0040231"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18545","DOI":"10.1074\/jbc.M800784200","article-title":"CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor","volume":"283","author":"Polyak","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar3909","article-title":"Rationale of anti-CD19 immunotherapy: An option to target autoreactive plasma cells in autoimmunity","volume":"14","author":"Schmidt","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.189.8.1307","article-title":"Deficiency in CD22, a B Cell\u2013specific Inhibitory Receptor, Is Sufficient to Predispose to Development of High Affinity Autoantibodies","volume":"189","author":"Williams","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nri2762","article-title":"Fc\u03b3RIIB in autoimmunity and infection: Evolutionary and therapeutic implications","volume":"10","author":"Smith","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/art.22211","article-title":"B cell depletion therapy in systemic lupus erythematosus: Effect on autoantibody and antimicrobial antibody profiles","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.autrev.2011.12.011","article-title":"B-cell directed therapies in antiphospholipid antibody syndrome \u2014 New directions based on murine and human data","volume":"11","author":"Khattri","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108180","DOI":"10.1016\/j.pharmthera.2022.108180","article-title":"Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease","volume":"238","author":"Chen","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_35","first-page":"1","article-title":"CD40 and Tolerance Induction","volume":"11","author":"Karimi","year":"2012","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12016-013-8378-7","article-title":"The Hyper IgM Syndromes","volume":"46","author":"Qamar","year":"2014","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e87310","DOI":"10.1172\/jci.insight.87310","article-title":"B cells from African American lupus patients exhibit an activated phenotype","volume":"1","author":"Menard","year":"2016","journal-title":"JCI Insight"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Duarte, J.H. (2015). ICOS sustains pathogenic T-cell survival in SLE mouse model. Nat. Rev. Rheumatol., 11.","DOI":"10.1038\/nrrheum.2015.49"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.immuni.2004.05.010","article-title":"Excess BAFF Rescues Self-Reactive B Cells from Peripheral Deletion and Allows Them to Enter Forbidden Follicular and Marginal Zone Niches","volume":"20","author":"Thien","year":"2004","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/art.38074","article-title":"Elevated serum B-cell activating factor (BAFF \/ BLyS) is associated with rising anti-dsDNA antibody levels and flare following B-cell depletion therapy in systemic lupus erythematosus: BAFF and SLE Relapse Following Rituximab","volume":"65","author":"Carter","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.05.003","article-title":"Role of TWEAK in Lupus Nephritis: A bench-to-bedside review","volume":"39","author":"Michaelson","year":"2012","journal-title":"J. Autoimmun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12967-016-0846-4","article-title":"Fn14-Fc suppresses germinal center formation and pathogenic B cells in a lupus mouse model via inhibition of the TWEAK\/Fn14 Pathway","volume":"14","author":"Min","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e000061","DOI":"10.1136\/lupus-2014-000061","article-title":"Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy","volume":"2","author":"Parodis","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1172\/JCI120859","article-title":"Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted","volume":"128","author":"Tilstra","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102424","DOI":"10.1016\/j.jaut.2020.102424","article-title":"JAK\/STAT signaling controls the fate of CD8+CD103+ tissue-resident memory T cell in lupus nephritis","volume":"109","author":"Zhou","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13075-016-1034-x","article-title":"JAK3-STAT pathway blocking benefits in experimental lupus nephritis","volume":"18","author":"Ripoll","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ittah, M., Miceli-Richard, C., Gottenberg, J.E., Lavie, F., Lazure, T., Ba, N., Sellam, J., Lepajolec, C., and Mariette, X. (2006). B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sj\u00f6gren\u2019s syndrome. Arthritis Res. Ther., 8.","DOI":"10.1186\/ar1912"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I Interferon in the Pathogenesis of Lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4049\/jimmunol.1100631","article-title":"Induction of Type I IFN Is a Physiological Immune Reaction to Apoptotic Cell-Derived Membrane Microparticles","volume":"189","author":"Schiller","year":"2012","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13075-019-1878-y","article-title":"High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus","volume":"21","author":"Oke","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatology"},{"key":"ref_53","first-page":"791","article-title":"Histopathology and molecular pathology of synovial B-lymphocytes in rheumatoid arthritis","volume":"15","author":"Krenn","year":"2000","journal-title":"Histol. Histopathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"859380","DOI":"10.3389\/fimmu.2022.859380","article-title":"Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2014.04.002","article-title":"Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review","volume":"44","author":"Longo","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e000442","DOI":"10.1136\/lupus-2020-000442","article-title":"Efficacy and safety of rituximab biosimilar in refractory lupus","volume":"7","author":"Pongtarakulpanit","year":"2020","journal-title":"Lupus Sci. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jamadermatol.2018.3793","article-title":"Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus","volume":"154","author":"Isenberg","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii\/iii systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40674-014-0003-2","article-title":"Rituximab: The Lupus Journey","volume":"1","author":"Ramos","year":"2015","journal-title":"Curr. Treat. Options Rheumatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrrheum.2016.18","article-title":"The BAFFling effects of rituximab in lupus: Danger ahead?","volume":"12","author":"Ehrenstein","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 Update of the Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","volume":"79","author":"Fanouriakis","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/keac471","article-title":"Rituximab as maintenance therapy following remission induction in relapsing or refractory systemic lupus erythematosus","volume":"62","author":"Chen","year":"2023","journal-title":"Rheumatology"},{"key":"ref_64","first-page":"3","article-title":"Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence","volume":"377","author":"Adams","year":"1995","journal-title":"Nature"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: The anti-BLyS\u2013lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/art.24699","article-title":"A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus","volume":"61","author":"Wallace","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","article-title":"A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea","volume":"77","author":"Zhang","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, Randomized, Fifty-Two \u2013Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","article-title":"Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial","volume":"79","author":"Penades","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two\u2013Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/0961203312465781","article-title":"Effect of belimumab treatment on renal outcomes: Results from the phase 3 belimumab clinical trials in patients with SLE","volume":"22","author":"Dooley","year":"2013","journal-title":"Lupus"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1093\/rheumatology\/keaa796","article-title":"De novo lupus nephritis during treatment with belimumab","volume":"60","author":"Parodis","year":"2020","journal-title":"Rheumatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/03009742.2014.887769","article-title":"Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity","volume":"43","year":"2014","journal-title":"Scand. J. Rheumatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.semarthrit.2016.09.006","article-title":"New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab","volume":"46","author":"Staveri","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): A multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e000534","DOI":"10.1136\/lupus-2021-000534","article-title":"Risk of psychiatric disorders and all-cause mortality with belimumab therapy in patients with systemic lupus erythematosus: A meta-analysis of randomised controlled trials","volume":"8","author":"Xie","year":"2021","journal-title":"Lupus Sci. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ramaswamy, M., Tummala, R., Streicher, K., da Costa, A.N., and Brohawn, P.Z. (2021). The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011286"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial","volume":"1","author":"Morand","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/annrheumdis-2021-221847","article-title":"Concordance and discordance in SLE clinical trial outcome measures: Analysis of three anifrolumab phase 2\/3 trials","volume":"81","author":"Bruce","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"Moser","year":"2010","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Aroca","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4049\/jimmunol.0903888","article-title":"Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice","volume":"185","author":"Meyer","year":"2010","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/0961203315574558","article-title":"First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus","volume":"24","author":"Tocoian","year":"2015","journal-title":"Lupus"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Bruce","year":"2021","journal-title":"Rheumatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.4049\/jimmunol.165.11.6037","article-title":"BDCA-2, BDCA-3, and BDCA-4: Three Markers for Distinct Subsets of Dendritic Cells in Human Peripheral Blood","volume":"165","author":"Dzionek","year":"2000","journal-title":"J. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/art.11225","article-title":"Expression of the markers BDCA-2 and BDCA-4 and production of interferon-\u03b1 by plasmacytoid dendritic cells in systemic lupus erythematosus: BDCA-2\/4 Expression and IFN\u03b1 Production in SLE","volume":"48","author":"Blomberg","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fimmu.2020.00433","article-title":"Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders","volume":"11","author":"Kaegi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/art.21489","article-title":"Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus","volume":"52","author":"Carter","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1136\/annrheumdis-2013-205067","article-title":"Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)","volume":"74","author":"Isenberg","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/art.40360","article-title":"Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus","volume":"70","author":"Merrill","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: Results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1093\/rheumatology\/keab115","article-title":"Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus","volume":"60","author":"Wallace","year":"2021","journal-title":"Rheumatology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_108","unstructured":"(2023, March 25). A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study. ACR Meeting Abstracts n.d. Available online: https:\/\/acrabstracts.org\/abstract\/a-human-recombinant-fusion-protein-targeting-b-lymphocyte-stimulator-blys-and-a-proliferation-inducing-ligand-april-telitacicept-rc18-in-systemic-lupus-erythematosus-sle-results-of-a-phase\/."},{"key":"ref_109","unstructured":"(2023, March 25). Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study. ACR Meeting Abstracts n.d. Available online: https:\/\/acrabstracts.org\/abstract\/telitacicept-a-human-recombinant-fusion-protein-targeting-b-lymphocyte-stimulator-blys-and-a-proliferation-inducing-ligand-april-in-systemic-lupus-erythematosus-sle-results-of-a-phase-3-study\/."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/09612033221141253","article-title":"The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: A real life observational study","volume":"32","author":"Chen","year":"2023","journal-title":"Lupus"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","article-title":"Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: Results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Merrill","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","article-title":"Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: Results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study","volume":"75","author":"Petri","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","article-title":"A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study","volume":"74","author":"Leon","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/annrheumdis-2012-202760","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study","volume":"73","author":"Wallace","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","article-title":"Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): Results from a randomised, double-blind, placebo-controlled trial","volume":"77","author":"Merrill","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results from Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis","volume":"73","author":"Malkiel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.7326\/M21-2078","article-title":"Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial","volume":"174","author":"Shipa","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_120","unstructured":"Aranow, C. (2023, March 20). Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study. ACR Meeting Abstracts n.d. Available online: https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-subcutaneous-belimumab-bel-and-rituximab-rtx-sequential-therapy-in-patients-with-systemic-lupus-erythematosus-the-phase-3-randomized-placebo-controlled-bliss-believe-stud\/."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"102240","DOI":"10.1016\/j.ctrv.2021.102240","article-title":"The promise of bispecific antibodies: Clinical applications and challenges","volume":"99","author":"Lim","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.rinim.2012.11.001","article-title":"A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis","volume":"2","author":"Rodriguez","year":"2012","journal-title":"Results Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_125","first-page":"100299","article-title":"From monogenic lupus to TLR7\/MyD88-targeted therapy","volume":"3","author":"Wang","year":"2022","journal-title":"Innovation"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"rkz021","DOI":"10.1093\/rap\/rkz021","article-title":"Integrated safety profile of atacicept: An analysis of pooled data from the atacicept clinical trial programme","volume":"3","author":"Gordon","year":"2019","journal-title":"Rheumatol. Adv. Pr."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/9\/3198\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:26:22Z","timestamp":1760124382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/9\/3198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":126,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12093198"],"URL":"https:\/\/doi.org\/10.3390\/jcm12093198","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,29]]}}}